Anna Megdell

Rogel Cancer Center researchers study how epigenetics regulates cancer-related genes, aiming to improve therapies, prevention strategies, and patient outcomes.

Komzifti (ziftomenib), developed at Michigan Medicine, has been approved for patients with acute myeloid leukemia caused by the NPM1 gene mutation.

Michigan Medicine findings suggest further investigation of FISH-negative tests for renal cell carcinoma could lead to more accurate diagnosis.

Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling.

Sidney Ritchie’s aggressive brain cancer diagnosis has changed her life, and now, in her new reality, she finds meaning and purpose through connection, volunteering, and “showing up fully”

Mike Nagle’s osteosarcoma journey, before he even had symptoms, was nothing short of a miracle, he explains in this article.

A study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

Avapritinib, an FDA-approved drug used to treat other types of cancer, also decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma.

The Rogel and Blondy Center for Pancreatic Cancer is a center of excellence in pancreatic cancer research, combining pioneering research with innovative clinical care and an array of clinical trials. Center co-director Marina Pasca di Magliano explains that the key to a robust research program and responsive care lies in collaboration.

A study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.

A study finds giving a fatty acid inhibitor alongside chemotherapy could improve the treatment efficacy for patients with brain metastases from triple negative breast cancer

A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance.

Researchers from the University of Michigan Health Rogel Cancer Center have discovered a biomarker that could help identify which renal cancer patients have a higher risk of recurrence.

Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.

When white blood cells, meant to protect the body from infection, are overly activated, they eject their DNA into nets, further disrupting the immune system and making patients more likely to develop a potentially severe reaction to immunotherapy.